Thoracic Tumor
Comparative analysis of clinical efficacy between stereotactic ablative radiotherapy and surgery for early-stage non-small cell lung cancer
Yingying Cui, Chengcheng Fan, Yanan Sun, Hui Luo, Xiaoli Zheng, Chengliang Yang, Ke Ye, Hong Ge
Published 2018-04-15
Cite as Chin J Radiat Oncol, 2018, 27(4): 365-369. DOI: 10.3760/cma.j.issn.1004-4221.2018.04.006
Abstract
ObjectiveTo compare the clinical efficacy and safety between stereotactic ablative radiotherapy (SABR) and surgery in the treatment of early-stage non-small cell lung cancer (NSCLC).
MethodsA total of 227 patients who were initially diagnosed with early-stage NSCLC and with complete clinical data admitted to Henan Cancer Hospital between June 2012 and December 2016 were recruited and assigned into the SABR (n=73) and surgery groups (n=154). Kaplan-Meier method was used to calculate survival rate and survival comparison was performed using the log-rank test. Chi-square test was adopted to compare the baseline data between two groups.
ResultsAll patients completed corresponding treatment. The samples of SABR group and operation group were 74 and 155 cases respectively. The 1-year and 3-year overall survival (OS) rates in the SABR and surgery groups were 97.2%, 81.9% and 96.5%, 78.2%(P=0.603), respectively. The 1-year and 3-year progression-free survival (PFS) rates in the SABR and surgery groups were 90.1%, 66.9% and 89.2%, 66.9%(P=0.565), respectively. The 1-year and 3-year locoregional recurrence-free survival rates in the SABR and surgery groups were 92.8%, 84.0% and 96.5%, 90.8%(P=0.133), respectively. The 1-year and 3-year distant metastasis-free survival rates in the SABR and surgery groups were 97.2%, 75.4% and 89.2%, 69.8%(P=0.095), respectively.
ConclusionsSABR and surgery yield similar OS, PFS, locoregional recurrence-free and distant metastasis-free survival rates in the treatment of early-stage NSCLC. Therefore, SABR is an alternative treatment for patients with early-stage NSCLC.
Key words:
Carcinoma, non-small cell lung/radiotherapy; Radiotherapy, stereotactic ablative; Prognosis
Contributor Information
Yingying Cui
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Chengcheng Fan
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Yanan Sun
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Hui Luo
Zhengzhou University Second Clinical College, Zhengzhou 450016, China
Xiaoli Zheng
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Chengliang Yang
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Ke Ye
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
Hong Ge
Department of Radiation Oncology, Henan Cancer Hospital, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China
